Geoffrey Von Maltzahn
About Geoffrey Von Maltzahn
Geoffrey Von Maltzahn is a prominent entrepreneur and researcher in the biotechnology field, serving as the Founding CEO and Chairman of the Board at Tessera Therapeutics since 2018. He has co-founded multiple companies, including Kaleido Biosciences and Cobalt Biomedicine, and holds advanced degrees in Bioengineering and Biomedical Engineering from the University of California, San Diego and the Massachusetts Institute of Technology.
Work at Tessera Therapeutics
Geoffrey Von Maltzahn serves as the Founding CEO and Chairman of the Board at Tessera Therapeutics, a role he has held since 2018. The company is based in Cambridge, Massachusetts, and focuses on advancing genetic medicines. Under his leadership, Tessera Therapeutics aims to innovate in the field of therapeutic solutions.
Work at Kaleido Biosciences
Geoffrey Von Maltzahn is the Founding CEO and Board Member of Kaleido Biosciences, a position he has maintained since 2015. The company operates out of Cambridge, Massachusetts, and is dedicated to developing microbiome-based therapies. His involvement has been instrumental in shaping the company's strategic direction.
Education and Expertise
Geoffrey Von Maltzahn earned a Master of Science in Bioengineering from the University of California, San Diego, where he studied from 2003 to 2005. He furthered his education at the Massachusetts Institute of Technology, obtaining a PhD in Biomedical Engineering and Medical Physics from 2005 to 2010. Additionally, he holds a Bachelor of Science in Chemical Engineering from MIT, which he completed from 1999 to 2003.
Achievements
Geoffrey Von Maltzahn has received over 20 awards and honors, including recognition in Business Insider's 30 under 40 young leaders and Endpoints 20 under 40. He was awarded the prestigious Lemelson-MIT Student Prize for his contributions to invention and innovation. He is also an inventor on over 200 patent applications and patents, showcasing his significant impact in the field.
Background in Biotechnology
Geoffrey Von Maltzahn has a robust background in biotechnology, having co-founded several companies, including Axcella Health and Seres Therapeutics. He played a key role in the discovery of SER-109 during his tenure as CTO at Seres Therapeutics. His work has been recognized by various prestigious organizations, including the World Economic Forum and Forbes.